Carcinogenic Effects of Nitrosodimethylamine Contamination in Ranitidine: Defining the Relationship With Renal Malignancies

Richard E. Link
{"title":"Carcinogenic Effects of Nitrosodimethylamine Contamination in Ranitidine: Defining the Relationship With Renal Malignancies","authors":"Richard E. Link","doi":"10.1097/ju9.0000000000000062","DOIUrl":null,"url":null,"abstract":"Patients with renal cell carcinoma (RCC) often feel struck by lightning. Unsatisfied by relatively modest associations of RCC with advancing age, male sex, tobacco exposure, and Western diets rich in red meat,1,2 patients reach for causative connections to occupational exposures and drugs. Exposure to trichloroethylene and chronic analgesic use has perhaps the most compelling association with RCC.3 However, many other drugs have been implicated in contributing to RCC without convincing proof. Urologists must be prepared to field these questions from their patients when they arise. The cautionary tale of the rise and fall of ranitidine, once the highest-selling drug on the planet, is fascinating and of particular interest to patients with RCC and their physicians. The downfall of ranitidine derived from the detection of a known carcinogen in the medication, nitrosodimethylamine (NDMA), linked to RCC and other tumors in animals. The authors describe the preclinical evidence for NDMA contamination in ranitidine, its connection to carcinogenesis in animals, and the challenges inherent in asking the critical clinical question: “Did ranitidine ingestion contribute to RCC tumorigenesis in humans?” The available population cohort data exploring this association are clouded by short follow-up, inhomogeneous data collection, the lack of screening imaging to detect subclinical tumors, and a range of other confounders. Moreover, NDMA levels were not actually measured in any of these studies. The story highlights the inherent difficulty in connecting an extremely pervasive drug exposure to a specific type of cancer unless the associated risk is exceptionally high. For practicing urologists, the take home message of this well-written review is that no clear association between ranitidine exposure and the development of RCC currently exists.4 However, the authors appropriately recommend that we view this conclusion, based entirely on observational studies with significant weaknesses, with caution when counseling our patients.","PeriodicalId":74033,"journal":{"name":"JU open plus","volume":"18 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JU open plus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/ju9.0000000000000062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Patients with renal cell carcinoma (RCC) often feel struck by lightning. Unsatisfied by relatively modest associations of RCC with advancing age, male sex, tobacco exposure, and Western diets rich in red meat,1,2 patients reach for causative connections to occupational exposures and drugs. Exposure to trichloroethylene and chronic analgesic use has perhaps the most compelling association with RCC.3 However, many other drugs have been implicated in contributing to RCC without convincing proof. Urologists must be prepared to field these questions from their patients when they arise. The cautionary tale of the rise and fall of ranitidine, once the highest-selling drug on the planet, is fascinating and of particular interest to patients with RCC and their physicians. The downfall of ranitidine derived from the detection of a known carcinogen in the medication, nitrosodimethylamine (NDMA), linked to RCC and other tumors in animals. The authors describe the preclinical evidence for NDMA contamination in ranitidine, its connection to carcinogenesis in animals, and the challenges inherent in asking the critical clinical question: “Did ranitidine ingestion contribute to RCC tumorigenesis in humans?” The available population cohort data exploring this association are clouded by short follow-up, inhomogeneous data collection, the lack of screening imaging to detect subclinical tumors, and a range of other confounders. Moreover, NDMA levels were not actually measured in any of these studies. The story highlights the inherent difficulty in connecting an extremely pervasive drug exposure to a specific type of cancer unless the associated risk is exceptionally high. For practicing urologists, the take home message of this well-written review is that no clear association between ranitidine exposure and the development of RCC currently exists.4 However, the authors appropriately recommend that we view this conclusion, based entirely on observational studies with significant weaknesses, with caution when counseling our patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
雷尼替丁中亚硝基二甲胺污染的致癌作用:确定与肾脏恶性肿瘤的关系
肾细胞癌(RCC)患者常有被雷击的感觉。不满意的是,RCC与年龄增长、男性、吸烟暴露和富含红肉的西方饮食之间存在相对有限的关联,1,2名患者将病因与职业暴露和药物联系起来。暴露于三氯乙烯和长期使用止痛药可能与RCC有最令人信服的联系。然而,许多其他药物也与RCC有关,但没有令人信服的证据。当病人提出这些问题时,泌尿科医生必须准备好回答。雷尼替丁曾经是这个星球上销量最高的药物,它的起起落落的警示故事令人着迷,对肾癌患者和他们的医生特别感兴趣。雷尼替丁的失败源于在药物中检测到一种已知的致癌物质,亚硝基二甲胺(NDMA),与RCC和其他动物肿瘤有关。作者描述了雷尼替丁中NDMA污染的临床前证据,它与动物致癌性的联系,以及提出关键临床问题所固有的挑战:“雷尼替丁摄入是否有助于人类RCC肿瘤的发生?”由于随访时间短、数据收集不均匀、缺乏检测亚临床肿瘤的筛查成像以及一系列其他混杂因素,探索这种关联的现有人群队列数据受到影响。此外,这些研究都没有实际测量NDMA水平。这个故事强调了将极其普遍的药物暴露与特定类型的癌症联系起来的固有困难,除非相关风险非常高。对于执业泌尿科医生来说,这篇写得很好的综述所传达的信息是,雷尼替丁暴露与肾癌发展之间目前还不存在明确的联系然而,作者恰当地建议我们在咨询患者时要谨慎看待这一结论,这一结论完全基于有明显弱点的观察性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Urinary Bladder Melanosis Diagnosed Simultaneously With Urothelial Carcinoma: A Case Report and Literature Review Artificial Intelligence–Generated Patient Information Videos for Partial Nephrectomy by Medical Students With Expert Validation: A Pilot Study Using a Reconstructive Ladder for Surgical Reconstruction of Transplant Ureteral Stricture Disease Editorial Comment: Telehealth in Urology Beyond COVID-19 Limitations of ChatGPT for Patient Education Regarding Frequently Searched Questions About Benign Prostatic Hyperplasia
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1